{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:40:02Z","timestamp":1761007202723,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.soc.2023.05.003","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T11:53:08Z","timestamp":1686397988000},"page":"693-703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evidence-Based Strategies to Minimize the Likelihood of Axillary Lymph Node Dissection in Clinically Node-Positive Patients Following Neoadjuvant Chemotherapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Ashley A.","family":"Woodfin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail S.","family":"Caudle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4S Suppl 3","key":"10.1016\/j.soc.2023.05.003_bib1","doi-asserted-by":"crossref","first-page":"S234","DOI":"10.1097\/SAP.0000000000001864","article-title":"Lymphedema Incidence After Axillary Lymph Node Dissection: Quantifying the Impact of Radiation and the Lymphatic Microsurgical Preventive Healing Approach","volume":"82","author":"Johnson","year":"2019","journal-title":"Ann Plast Surg"},{"issue":"10","key":"10.1016\/j.soc.2023.05.003_bib2","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1245\/s10434-017-5960-x","article-title":"Breast Cancer-Related Lymphedema Risk is Related to Multidisciplinary Treatment and Not Surgery Alone: Results from a Large Cohort Study","volume":"24","author":"Nguyen","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.soc.2023.05.003_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.21037\/gs.2017.11.04","article-title":"Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments","volume":"7","author":"Gillespie","year":"2018","journal-title":"Gland Surg"},{"issue":"5","key":"10.1016\/j.soc.2023.05.003_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/SLA.0000000000001778","article-title":"Does Axillary Reverse Mapping Prevent Lymphedema after Lymphadenectomy?","volume":"265","author":"Tummel","year":"2017","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.soc.2023.05.003_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2023.05.003_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.soc.2023.05.003_bib7","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.soc.2023.05.003_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00000658-199907000-00011","article-title":"Incidence and Impact of Documented Eradication of Breast Cancer Axillary Lymph Node Metastases Before Surgery in Patients Treated With Neoadjuvant Chemotherapy","volume":"230","author":"Kuerer","year":"1999","journal-title":"Ann Surg"},{"issue":"16","key":"10.1016\/j.soc.2023.05.003_bib9","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2\u2013Positive Operable Breast Cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.soc.2023.05.003_bib10","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/cncr.25152","article-title":"Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer","volume":"116","author":"Dominici","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soc.2023.05.003_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.surg.2005.03.003","article-title":"Factors predicting failure to identify a sentinel lymph node in breast cancer","volume":"138","author":"Chagpar","year":"2005","journal-title":"Surgery"},{"issue":"7","key":"10.1016\/j.soc.2023.05.003_bib12","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1245\/s10434-010-0945-z","article-title":"Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS Trial","volume":"17","author":"Straver","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2023.05.003_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/SLA.0000000000000551","article-title":"Factors Affecting Sentinel Lymph Node Identification Rate After Neoadjuvant Chemotherapy for Breast Cancer Patients Enrolled in ACOSOG Z1071 (Alliance)","volume":"261","author":"Boughey","year":"2015","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.soc.2023.05.003_bib14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/SLA.0b013e3181b8fd5e","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients","volume":"250","author":"Hunt","year":"2009","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.soc.2023.05.003_bib15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2008.18.3228","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: Results of ganglion sentinelle et chimioth\u00e9rapie neoadjuvante, a French prospective multicentric study","volume":"27","author":"Classe","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.soc.2023.05.003_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.soc.2023.05.003_bib17","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.soc.2023.05.003_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2023.05.003_bib19","doi-asserted-by":"crossref","unstructured":"Boughey J, et\u00a0al. Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy \u2013 Results from a prospective trial \u2013 ACOSOG Z1071 (Alliance). In: San Antonio Breast Cancer Symposium 2014. ; 2014 Available at: http:\/\/eposter.abstractsonline.com\/sabcs. Accessed January 30, 2015.","DOI":"10.1158\/1538-7445.SABCS14-P2-01-02"},{"issue":"4","key":"10.1016\/j.soc.2023.05.003_bib20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","article-title":"Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0\u2013T4, N1\u2013N2) Who Receive Neoadjuvant Chemotherapy","volume":"263","author":"Boughey","year":"2016","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.soc.2023.05.003_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jamasurg.2014.1086","article-title":"Selective Surgical Localization of Axillary Lymph Nodes Containing Metastases in Patients With Breast Cancer: A Prospective Feasibility Trial","volume":"150","author":"Caudle","year":"2015","journal-title":"JAMA Surg"},{"issue":"10","key":"10.1016\/j.soc.2023.05.003_bib22","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patientswith node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.soc.2023.05.003_bib23","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1097\/SLA.0000000000004572","article-title":"A\u00a0Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients","volume":"276","author":"Kuemmel","year":"2022","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.soc.2023.05.003_bib24","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/jamasurg.2022.3907","article-title":"Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla with Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Node-Positive Breast Cancer","volume":"157","author":"Simons","year":"2022","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.soc.2023.05.003_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","article-title":"Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients the mari procedure","volume":"261","author":"Donker","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.soc.2023.05.003_bib26","unstructured":"EUBREAST Network: AXillary Surgery After Neoadjuvant Treatment (AXSANA). EUBREAST Network. Accessed January 1, 2023. Available at: https:\/\/www.eubreast.com\/?Trials\/AXSANA."},{"key":"10.1016\/j.soc.2023.05.003_bib27","article-title":"Safely Avoiding Axillary Lymphadenectomy after Neoadjuvant Chemotherapy for Patients with Proven Axillary Lymph Node Involvement Early Breast Cancer? The French Multicenter Prospective Ongoing GANEA 3 Study","volume":"5","author":"Loaec","year":"2020","journal-title":"Clin Surg"},{"issue":"4","key":"10.1016\/j.soc.2023.05.003_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","article-title":"Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial","volume":"14","author":"Galimberti","year":"2013","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.soc.2023.05.003_bib29","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA, J Am Med Assoc"},{"issue":"11","key":"10.1016\/j.soc.2023.05.003_bib30","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","article-title":"Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer","volume":"26","author":"Wong","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2023.05.003_bib31","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","article-title":"Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?","volume":"25","author":"Moo","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.soc.2023.05.003_bib32","article-title":"Oncological Outcomes Following Omission of Axillary Lymph Node Dissection in Node Positive Patients Downstaging To Node Negative with Neoadjuvant Chemotherapy: the OPBC-04\/EUBREAST-06\/OMA study","volume":"83","author":"Montagna","year":"2023","journal-title":"Canc Res"},{"issue":"12","key":"10.1016\/j.soc.2023.05.003_bib33","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","article-title":"Nodal Recurrence in Patients with Node-Positive Breast Cancer Treated with Sentinel Node Biopsy Alone after Neoadjuvant Chemotherapy - A Rare Event","volume":"7","author":"Barrio","year":"2021","journal-title":"JAMA Oncol"},{"issue":"15_suppl","key":"10.1016\/j.soc.2023.05.003_bib34","doi-asserted-by":"crossref","first-page":"TPS600","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS600","volume":"37","author":"Mamounas","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2023.05.003_bib35","article-title":"Alliance A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Receiving Neoadjuvant Chemotherapy","author":"Boughey","year":"2019","journal-title":"Alliance: For Clinical Trials in Oncology"},{"issue":"10","key":"10.1016\/j.soc.2023.05.003_bib36","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1245\/s10434-017-5958-4","article-title":"Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members","volume":"24","author":"Caudle","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2023.05.003_bib37","unstructured":"Rashmi Kumar N, Berardi R, Abraham J, et\u00a0al. NCCN Guidelines Version 4.2022 Breast Cancer; 2022. https:\/\/www.nccn."}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320723000418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320723000418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:06:10Z","timestamp":1760961970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320723000418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1055320723000418"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2023.05.003","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-Based Strategies to Minimize the Likelihood of Axillary Lymph Node Dissection in Clinically Node-Positive Patients Following Neoadjuvant Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2023.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}